🌍 Worldwide🎗️ Cancer & Oncology📡 OpenAlex🕒 Updated November 2, 2026

Most-Cited CAR-T Cell Therapy Papers This Year (2026)

As of November 2, 2026, “Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial” leads Most-Cited CAR-T Cell Therapy Papers This Year with 54 citations. “In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study” is second and “In vivo site-specific engineering to reprogram T cells” third.

WhatsApp Telegram X Facebook ⓘ Methodology

🚫 No paid placement📡 Source: OpenAlex🕒 Updated November 2, 2026 ⓘ How we measure

🎗️2

In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 studyNing An et al. · Nature Medicine · 2026-03-2546 citations

👑

🎗️1

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trialHermann Einsele et al. · The Lancet Oncology · 2026-01-0754 citations

🎗️3

In vivo site-specific engineering to reprogram T cellsWilliam A. Nyberg et al. · Nature · 2026-03-1845 citations

Full ranking

🎗️

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial ↗ •🏆 Leader

Hermann Einsele et al. · The Lancet Oncology · 2026-01-07

54 citationsCitations

🎗️

In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study ↗ •

Ning An et al. · Nature Medicine · 2026-03-25

46 citationsCitations

🎗️

In vivo site-specific engineering to reprogram T cells ↗ •

William A. Nyberg et al. · Nature · 2026-03-18

45 citationsCitations

🎗️

Critical role for a high-plasticity cell state in lung cancer ↗ •

Jason Earl Chan et al. · Nature · 2026-01-21

38 citationsCitations

🎗️

BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial ↗ •

Tuan Vu et al. · Nature Medicine · 2026-01-09

35 citationsCitations

🎗️

Anti-FAP CAR T cells produced in vivo reduce fibrosis and restore liver homeostasis in metabolic dysfunction–associated steatohepatitis ↗ •

Chittampalli N. Yashaswini et al. · Science Translational Medicine · 2026-01-21

29 citationsCitations

🎗️

RETRACTED ARTICLE: Engineered outer membrane vesicles enhance solid tumour CAR-T cell therapy ↗ •

Xianjun Li et al. · Nature Biomedical Engineering · 2026-01-07

26 citationsCitations

🎗️

Tumor-antigen-independent targeting of solid tumors by armored macrophage-directed anti-TREM2 CAR T cells ↗ •

Gal Yagel et al. · Cancer Cell · 2026-01-22

22 citationsCitations

🎗️

CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy ↗ •

Matthew Ho et al. · Nature Medicine · 2026-01-15

21 citationsCitations

🎗️

BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial ↗ •

Renee Fedak et al. · Nature Medicine · 2026-01-09

21 citationsCitations

How this ranking works

Ranked by citation count (OpenAlex) among research papers published this year whose title or abstract matches this topic. Citations build up over time, so the newest papers rank lower. For information only, not medical advice.

Methodology →

SourceOpenAlex

SignalCitations

Last updatedNov 2, 2026, 4:27 PM UTC

Top 10Citations of papers published this year

Frequently asked questions

What is #1 in Most-Cited CAR-T Cell Therapy Papers This Year?

As of November 2, 2026, #1 is “Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial”.

How is this ranking measured?

How often is this chart updated?

Data is re-collected automatically and every page shows its last update date.

Can a brand pay to appear in this ranking?

No. There are no paid placements and no commercial influence on rank.